Literature DB >> 1988368

Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA.

S J Russell1, S A Eccles, C L Flemming, C A Johnson, M K Collins.   

Abstract

The notion that tumour-cell-derived IL-2 might lead to paracrine stimulation of the host anti-tumour response was tested in a transplantable rat sarcoma model. Three HSNLV clones induced to secrete different amounts of human IL-2 following retroviral gene transfer showed reduced tumorigenicity and metastatic potential in athymic (nu/nu) and immunocompetent syngeneic rats which was directly related to the level of IL-2 secretion. In contrast, the tumorigenicity of HSNLV clones secreting a biologically inactive form of IL-2 (IL-2Lys20) was unaltered. T-lymphocyte-mediated rejection of ZipI, the highest IL-2 producer, was demonstrated histologically in hooded rats and infiltrating mononuclear cells were also observed in ZipI tumours growing in athymic rats. Tumours derived from IL-2-secreting HSNLV showed reduced or absent IL-2 secretion in immunocompetent rats, sometimes with associated loss of the IL-2 provirus, but continued to secrete IL-2 in nude rats. The host response to Moloney-helper-virus-infected HSNLV was also examined and the results represent a cautionary note to those undertaking experiments of a similar nature.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988368     DOI: 10.1002/ijc.2910470213

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

Review 1.  Retroviral vectors. From laboratory tools to molecular medicine.

Authors:  R G Vile; A Tuszynski; S Castleden
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

Review 2.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 4.  Strategies for cancer gene therapy using adenoviral vectors.

Authors:  V Descamps; M T Duffour; M C Mathieu; N Fernandez; L Cordier; M A Abina; E Kremer; M Perricaudet; H Haddada
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

5.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.

Authors:  H Hock; M Dorsch; U Kunzendorf; Z Qin; T Diamantstein; T Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

Review 6.  Strategies for cytokine utilisation in tumor therapy.

Authors:  F Di Pierro; F Cavallo; F Pericle; S Bertini; M Giovarelli; G Forni
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

7.  Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected L1210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression; potential therapeutic implications.

Authors:  P K Chakravarty; H Fuji; M M Abu-Hadid; S C Hsu; A K Sood
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 8.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

9.  MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.

Authors:  T S Kim; E P Cohen
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

10.  Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors.

Authors:  M P Colombo; L Lombardi; C Melani; M Parenza; C Baroni; L Ruco; A Stoppacciaro
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.